Literature DB >> 27309261

Serum lactate dehydrogenase is a predictor of poor survival in malignant melanoma.

Dong Gao1, Xianying Ma2.   

Abstract

INTRODUCTION: Recently, different studies suggested that the elevated serum concentration of lactate dehydrogenase (LDH) was associated with poor prognosis of melanoma. However, the results were controversial.
BACKGROUND: We decided to perform a meta-analysis to assess the association between serum concentration of LDH and the overall survival (OS) of melanoma. EVIDENCE ACQUISITION: Online electronic databases (PubMed, EMBASE, and Cochrane database) were searched. The association of LDH and the OS of melanoma was estimated by hazard ratio (HR) with its 95% confidence interval (CI). EVIDENCE SYNTHESIS: A total of 13 eligible studies with 4036 patients met the inclusion criteria. LDH level was significantly associated with OS in melanoma patients (HR=1.97, 95% CI 1.62-2.40, P<0.00001; I2=78%). In addition, LDH level was also significantly associated with OS in stage IV melanoma patients (HR=1.99, 95% CI 1.59-2.50, P<0.00001; I2=79%). In the subgroup analysis by study design, a statistically significant association was found in retrospective cohort studies (HR=2.31, 95% CI 1.18- 4.51, P=0.01; I2=87%) and in prospective cohort studies (HR=1.87, 95% CI 1.55-2.26, P<0.00001; I2=73%). In the subgroup analysis by sample size, LDH level was significantly associated with OS in large sample size studies (HR=1.61, 95% CI 1.17-2.23, P=0.003; I2=73%) and small sample size studies (HR=2.18, 95% CI 1.69-2.80, P <0.00001; I2=79%).
CONCLUSIONS: In conclusion, this meta-analysis suggested that high LDH level might be a predictor of poor prognosis of melanoma patients.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27309261     DOI: 10.23736/S0031-0808.16.03216-X

Source DB:  PubMed          Journal:  Panminerva Med        ISSN: 0031-0808            Impact factor:   5.197


  5 in total

1.  Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer.

Authors:  Seyed Pairawan; Kenneth R Hess; Filip Janku; Nora S Sanchez; Kenna R Mills Shaw; Cathy Eng; Senthilkumar Damodaran; Milind Javle; Ahmed O Kaseb; David S Hong; Vivek Subbiah; Siqing Fu; David R Fogelman; Victoria M Raymond; Richard B Lanman; Funda Meric-Bernstam
Journal:  Clin Cancer Res       Date:  2019-12-18       Impact factor: 12.531

2.  Predictors of survival in metastatic melanoma patients with leptomeningeal disease (LMD).

Authors:  Sherise D Ferguson; Shivani Bindal; Roland L Bassett; Lauren E Haydu; Ian E McCutcheon; Amy B Heimberger; Jing Li; Barbara J O'Brien; Nandita Guha-Thakurta; Michael T Tetzlaff; Hussein Tawbi; Michael A Davies; Isabella C Glitza
Journal:  J Neurooncol       Date:  2019-03-07       Impact factor: 4.130

Review 3.  Biomarkers Predictive of Survival and Response to Immune Checkpoint Inhibitors in Melanoma.

Authors:  Emanuelle M Rizk; Angelina M Seffens; Megan H Trager; Michael R Moore; Larisa J Geskin; Robyn D Gartrell-Corrado; Winston Wong; Yvonne M Saenger
Journal:  Am J Clin Dermatol       Date:  2020-02       Impact factor: 7.403

4.  Serum parameters as prognostic biomarkers in a real world cancer patient population treated with anti PD-1/PD-L1 therapy.

Authors:  Christoph Minichsdorfer; Andreas Gleiss; Marie-Bernadette Aretin; Manuela Schmidinger; Thorsten Fuereder
Journal:  Ann Med       Date:  2022-12       Impact factor: 5.348

Review 5.  Multidisciplinary Care of BRAF-Mutant Stage III Melanoma: A Physicians Perspective Review.

Authors:  Lynn A Cornelius; Ryan C Fields; Ahmad Tarhini
Journal:  Oncologist       Date:  2021-06-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.